paclitaxel cationic liposome (CSPCHA131) / CSPC Pharma - LARVOL DELTA

HA131 (hepatic arterial infusion) in combination with systemic therapy (XELOX with or without bevacizumab) as first-line treatment in gastrointestinal cancer with liver metastases: A prospective study. (ASCO 2026) - P=N/A | "Up to the present, there have been no relevant reports on the application of liposomal paclitaxel formulation in combined systemic treatment of gastrointestinal cancer with liver metastasis. This regimen demonstrated manageable safety and notably primary efficacy, warranting further exploration in patients with gastrointestinal cancer and liver metastases."

Clinical • Combination therapy • Gastrointestinal Cancer • Hepatology • Oncology • Solid Tumor • Thrombocytopenia

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer (clinicaltrials.gov) - P1/2 | N=116 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

New P1/2 trial • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

A Study of CSPCHA131 in Patients With Advanced Solid Tumor (clinicaltrials.gov) - P1; N=100; Recruiting; Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Oncology • Solid Tumor

A Study of CSPCHA131 in Patients With Advanced Solid Tumor (clinicaltrials.gov) - P1; N=100; Not yet recruiting; Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Clinical • New P1 trial